Guizhou Yibai Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600594.SS

Guizhou Yibai Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) on January 27, 2025: 25.42

Guizhou Yibai Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) is 25.42 on January 27, 2025, a -34.20% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Guizhou Yibai Pharmaceutical Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 38.63 on January 29, 2024, which is 51.98% above the current Price to Earnings Ratio (P/E).
Guizhou Yibai Pharmaceutical Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is 21.96 on July 10, 2024, which is -13.61% below the current Price to Earnings Ratio (P/E).
Guizhou Yibai Pharmaceutical Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 28.44.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Shanghai Stock Exchange: 600594.SS

Guizhou Yibai Pharmaceutical Co., Ltd.

CEO	Ms. Ya Qi Dou
IPO Date	March 23, 2004
Location	China
Headquarters	No. 220-1, Baiyun Avenue
Employees	5,509
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years